Underlying Mechanism: Defective LDL Receptor Function in Familial Hypercholesterolemia
This patient has familial hypercholesterolemia (FH), most likely heterozygous FH, caused by mutations in genes encoding the LDL receptor (LDLR), apolipoprotein B-100 (APOB), or PCSK9, which impair hepatic clearance of LDL particles from the circulation, leading to markedly elevated LDL-cholesterol with normal triglycerides. 1, 2
Pathophysiologic Mechanism
The core defect in FH involves impaired hepatic uptake of LDL particles through one of three primary genetic pathways 3:
- LDLR gene mutations (most common, >700 variants identified): These produce defective or absent LDL receptors on hepatocyte surfaces, preventing normal binding and internalization of LDL particles 4, 3
- APOB gene mutations: These create defective apolipoprotein B-100, which cannot properly bind to LDL receptors even when receptors are structurally normal 2
- PCSK9 gene mutations (gain-of-function): These increase degradation of LDL receptors, reducing their availability on hepatocyte surfaces 1
Why Cholesterol is Elevated but Triglycerides Remain Normal
The selective elevation of LDL-cholesterol with normal triglycerides occurs because FH specifically disrupts the LDL receptor-mediated clearance pathway, which primarily removes cholesterol-rich LDL particles, while leaving the triglyceride clearance pathways intact. 1
Here's the mechanistic distinction:
LDL Pathway (Impaired in FH):
- LDL particles are cholesterol-rich, triglyceride-poor lipoproteins
- Normally cleared via hepatic LDL receptors through receptor-mediated endocytosis
- In FH, defective receptors cause LDL particles to accumulate in plasma, dramatically elevating cholesterol levels from birth 4, 5
- This patient's LDL-C of 460 mg/dL (normal <100 mg/dL) reflects this impaired clearance
Triglyceride Pathway (Intact in FH):
- Triglycerides are primarily carried in VLDL and chylomicrons
- Cleared via lipoprotein lipase (LPL) in peripheral tissues and hepatic remnant receptors (LRP, not LDLR)
- These pathways remain functional in FH, maintaining normal triglyceride metabolism 6
- This patient's triglycerides of 134 mg/dL and VLDL of 27 mg/dL are within normal range
Clinical Correlation Supporting FH Diagnosis
This patient's presentation is pathognomonic for heterozygous FH 2, 4:
- Early-onset xanthomas (since age 2): Cutaneous/tendon xanthomas result from cholesterol deposition in macrophages forming foam cells 7, 5
- Extreme LDL-C elevation (460 mg/dL): Consistent with heterozygous FH (typically 200-400 mg/dL) 5
- Strong family history: Multiple premature deaths from MI at ages 36-44 years indicates autosomal dominant inheritance 2
- Normal triglycerides: Rules out combined hyperlipidemia or secondary causes 6
Risk Stratification
This patient faces a 10- to 22-fold increased risk of premature atherosclerotic cardiovascular disease compared to the general population 2. The family history of MI in the 30s-40s confirms this extreme risk. Without treatment, approximately 80% of males and 20-30% of females with heterozygous FH develop ischemic heart disease by age 50 5.
Critical Next Steps
Genetic testing should be offered immediately to confirm the diagnosis and identify the specific mutation, which enables cascade screening of family members and refines cardiovascular risk stratification 1, 2. Patients with confirmed FH-causing variants have significantly higher ASCVD risk than those with polygenic hypercholesterolemia 2.
Common Pitfall to Avoid
Do not delay treatment while awaiting genetic testing results. The inability to detect an FH-causing variant should never be used as justification to withhold lipid-lowering therapy in patients with clinical FH 2. The diagnosis is clinical, and genetic testing serves to confirm and facilitate family screening, not to determine treatment eligibility.
Immediate referral to a lipid specialist is mandatory for comprehensive cardiovascular evaluation and aggressive lipid-lowering therapy, ideally targeting LDL-C <55 mg/dL or at least 50% reduction from baseline 1, 4.